Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02544373 · ClinicalTrials.gov registry record · NA

CPAP to Treat Cognitive Dysfunction in MS

A NA study of Multiple Sclerosis, sponsored by University of Michigan.

Completed
Registry status
NA
Development phase
135
Enrollment target
1
Study location

NCT02544373 is a NA study of Multiple Sclerosis that has completed, run by University of Michigan. The registered enrollment target is 135 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02544373, a NA study of Multiple Sclerosis, has completed, sponsored by University of Michigan.

COMPLETED
Registry status
NA
Development phase
135 participants
Enrollment target
1
Study location

Study Summary

The objectives of this study are to determine the effects of obstructive sleep apnea (OSA) on cognitive function in patients with multiple sclerosis (MS); and to evaluate whether OSA treatment with positive airway pressure therapy could improve cognitive dysfunction in MS patients who have OSA.

Conditions Studied

Interventions

  • DEVICE PAP therapy

Study Locations (1)

Michigan

  • University of Michigan Medical Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 135 participants
Start Date 2015-11-12
Est. Completion 2021-06-25
Phase NA

Sponsor

University of Michigan

1,327 total trials

What the Registry Record Tells You About NCT02544373

The ClinicalTrials.gov registry entry for NCT02544373 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (77% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which PAP therapy is the first listed.

NCT02544373 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT02544373 about?

NCT02544373 is a clinical study titled "CPAP to Treat Cognitive Dysfunction in MS". The objectives of this study are to determine the effects of obstructive sleep apnea (OSA) on cognitive function in patients with multiple sclerosis (MS); and to evaluate whether OSA treatment with positive airway pressure therapy could improve cognitive dysfunction in MS patients who have OSA.

What is the current status of trial NCT02544373?

This trial is currently completed. It is a NA study. The enrollment target is 135 participants. The study started on 2015-11-12. Estimated completion is 2021-06-25.

What conditions does trial NCT02544373 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT02544373?

The interventions under investigation include: PAP therapy (DEVICE).

Who is sponsoring clinical trial NCT02544373?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02544373 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.